Search International and National Patent Collections

1. (WO2016051213) PAR INHIBITION

Pub. No.:    WO/2016/051213    International Application No.:    PCT/GB2015/054026
Publication Date: Fri Apr 08 01:59:59 CEST 2016 International Filing Date: Thu Dec 17 00:59:59 CET 2015
IPC: A61K 31/496
A61P 9/00
A61P 39/00
Applicants: CLINIGEN GROUP PLC
Inventors: MCCORMACK, Keith
GEORGE, Peter
Title: PAR INHIBITION
Abstract:
The present invention relates to a compound capable of inhibiting PAR by forming a supramolecular structure with PAR, for use in inhibiting PAR or for use in treating or preventing a disease susceptible to PAR inhibition. The present invention further relates to a method of inhibiting PAR and a method of treating or preventing a disease susceptible to PAR inhibition, using a compound capable of inhibiting PAR by forming a supramolecular structure with PAR. Preferably the compound is dexrazoxane, levrazoxane, merbarone or mitindomide, or an analogue, derivative or metabolite thereof. The present invention also relates to a PAR inhibitor for use as a cardioprotective agent or for use in treating or preventing the cardiotoxic side effects of anthracyclines. The present invention further relates to a method of treating or preventing the cardiotoxic side effects of anthracyclines, using a PAR inhibitor. Furthermore, the present invention relates to a PAR inhibitor for use in treating or preventing extravasation. The present invention further relates to a method of treating or preventing extravasation, using a PAR inhibitor. Moreover, the present invention relates to a polymer of (i) polyadenylated RNA or DNA, and (ii) dexrazoxane, levrazoxane, merbarone or mitindomide, or an analogue, derivative or metabolite thereof, which may be used to treat or prevent a disease susceptible to PAR inhibition. Moreover, the present invention relates to a combination of a PAR inhibitor and a PARP inhibitor, or a combination of a PAR inhibitor and a second PAR inhibitor, which may be used to treat or prevent a disease susceptible to PAR inhibition. Lastly, the present invention relates to the use of dexrazoxane, levrazoxane, merbarone or mitindomide, or an analogue, derivative or metabolite thereof, for pre-treatment of mesenchymal stem cells.